Polynucleotides Injectables Market Size - By Application, By End Use, Forecast, 2025 - 2034

Polynucleotides Injectables Market Size

The polynucleotides injectables market was estimated at USD 127.8 million in 2024. The market is expected to grow from USD 145.7 million in 2025 to USD 525.7 million by 2034 at a CAGR of 15.3%. Polynucleotide injectables are innovated medical formulations which contains purified DNA fragments designed to promote tissue regeneration, minimize inflammation, and also improve hydration. These are extensively used in aesthetics and regenerative medicine to improve skin elasticity, repair damaged tissues, and support joint health.
 

The polynucleotide injectables market is expanding due to the rising demand for minimal invasive aesthetic procedures and regenerative medicine, projected to grow at CAGR of 20.4% and is expected to reach USD 328.9 billion by 2032. According to the International Society of Aesthetic Plastic Surgery (ISAPS), there was a 3.4% global increase in aesthetic procedures, with 34.9 million surgical and nonsurgical aesthetic treatments performed by plastic surgeons in 2023. This includes 15.8 million surgical procedures and 19.1 million nonsurgical procedures worldwide.
 

The demand for aesthetic treatments has shown a steady upward trend, particularly since 2021. Over the past four years, the total number of procedures has increased by 40%, reflecting the rising consumer preference for non-invasive and regenerative aesthetic solutions. Moreover, innovations such as polynucleotide-hyaluronic acid combinations provides dual benefits of hydration and regeneration.
 

Furthermore, favorable regulatory approvals and supportive policies are accelerating the growth of the polynucleotide injectables market. For instance, Rejuran, a polynucleotide-based injectable for dermal rejuvenation, received approval in 2023 for use in Australia and is included in the Australian Register of Therapeutic Goods (ARTG). This shows the increasing acceptance and regulatory support for polynucleotide injectables in the global market.
 

 Polynucleotides Injectables Market Trends

• Polynucleotide (PN) injectables are developing the field of aesthetic and regenerative medicine through advancements in formulation, delivery systems, and clinical applications.
   
• Recent innovations have improved the effectiveness of polynucleotide (PN) injectables through refined formulations that stimulate fibroblast activity, boost collagen production, and increase tissue repair. For example, NEWEST by Mastelli, launched in the UK, is the first product to combine polynucleotides with hyaluronic acid, offering better skin hydration, elasticity, and regeneration.
   
• Additionally, advancements in nanotechnology and bioengineering have led to the development of targeted delivery systems for polynucleotide injectables. Liposomal and hydrogel-based carriers improve the stability and penetration of PNs into the dermal layers, which improves cellular uptake and bioavailability for more effective skin rejuvenation. For example, Croma-Pharma has introduced Saypha Lips and Saypha Lips Lidocaine, advanced cross-linked hyaluronic acid dermal fillers designed specifically for lip augmentation, providing enhanced volume, definition, and natural-looking results.
   
• Furthermore, researchers are combining PNs with bioactive peptides, hyaluronic acid, and growth factors to increase their regenerative effects. These combination therapies improve wound healing, enhance elasticity, and speed up post-treatment recovery, which makes them ideal for anti-aging and scar reduction. This is driving the demand for advanced, minimally invasive aesthetic treatments.
   

Polynucleotides Injectables Market Analysis

Based on application, the polynucleotides injectable market includes eyes, lips, forehead, jawline and cheekbones, and other applications. The global market was estimated to reach USD 112.2 million in 2023. The eye segment held the largest revenue share of 62.3% in 2024, owing to rising demand for non-invasive solutions targeting under-eye concerns.
 

• The eye segment's dominance is mainly due to the effectiveness of polynucleotide injectables in treating under-eye hollows, wrinkles, and dark circles. These injectables stimulate dermal fibroblasts, promote collagen production, and enhance the extracellular matrix, which improves skin elasticity and reduces wrinkles.
   
• For example, Nucleofill Eyes is an injectable treatment which uses highly purified, low-molecular-weight polynucleotides (PN) of natural origin, to revitalise and rejuvenate the peri-ocular area. By targeting the root causes of under-eye concerns, Nucleofill promotes long-lasting improvements in skin texture, firmness, and hydration.
   
• These polynucleotide treatments involve micro-injections of fish-derived polynucleotides, specifically from salmon, which are known for their ability to repair UV-damaged fibroblasts and stimulate collagen types I and III production. This results in smoother, more hydrated, and rejuvenated skin around the eyes.
   
• With their ability to deliver natural-looking results with minimal downtime, polynucleotide injectables are mostly preferred by people seeking effective, non-surgical solutions, ensuring the eye segment remains the leading application in this market.
   

Based on end-use, the polynucleotide injectables market is segmented into medical spas, aesthetic and cosmetic centers, and hospitals. The medical spa segment accounted for a revenue share of 48.5% and with revenue of USD 62 million in 2024.
 

• Medical spas are becoming more convenient destinations for individuals seeking affordable and effective treatments, such as polynucleotide injectables, for skin rejuvenation and anti-aging.
   
• For instance, according to the American Med Spa Association in 2023, there were 8,841 registered medical spas in the United States. This large number shows the increasing demand for polynucleotide injectables.
   
• The non-invasive nature of polynucleotide injectables works well with the services offered by medical spas, which focus on quick recovery times and minimal discomfort for patients.
   
• Additionally, the rising demand for rejuvenating treatments in medical spas is supported by consumers seeking easy-to-access, convenient, and personalized aesthetic solutions, making this segment a leading player in the overall market.
   
• As the growing trend toward non-invasive cosmetic procedures continues, the medical spas segment is expected to maintain its leadership in the coming years.
   

North America polynucleotides injectable market accounted for USD 53 million revenues in 2024 and is predicted to witness substantial market growth over the analysis timeline. The U.S. market dominated the region with a revenue of USD 40.6 million in 2023.
 

• This growth can be largely attributed to the high disposable income in North America, especially in the U.S., which allows the consumers to spend on premium aesthetic procedures and self-care treatment, including the polynucleotides injectable treatments.
   
• For instance, according to the Statista, around 7.4 million people in the U.S. underwent the cosmetic procedures in 2022.
   
• Moreover, the influence of social media platform and beauty influencers plays a prominent role in shaping consumer preferences toward the smooth skin, further propelling the growth of the market in the region.
   

Europe: The polynucleotide injectables market in the UK is projected to experience steady growth between 2025 and 2034.
 

• The increasing population of the younger generation in the country is propelling the growth of the market.
   
• For instance, in 2022, as per data from the Statista, the younger generation population aged 18-25 years in the country was around 7.5 million. These demographic individuals embrace polynucleotide injectables as an efficient, effective, and long-term solution non-invasive solution for skin rejuvenation, hydration, and collagen stimulation, compared to traditional aesthetic treatments. Thus, this growing preference is significantly propelling the growth of the market.
   
• Additionally, the UK government is actively working to regulate non-surgical cosmetic procedures to ensure safety and quality. Such measures are expected to boost consumer confidence and support market growth for treatments such as polynucleotide injectables.
   

Asia Pacific: Japan polynucleotides injectables market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The rising number of aesthetic procedures performed in the country is strengthening the growth of the market.
   
• For example, according to Statista, in 2020, 835,600 non-invasive aesthetic procedures and 222,600 surgical aesthetic procedures were performed. Among these, polynucleotide injectable procedures are performed across the country.
   
• Moreover, Japan's strong cultural focus on aesthetics and flawless skin has fueled a growing demand for minimally invasive cosmetic procedures.
   
• Government policies supporting local research and development in biotechnology have contributed to the introduction of safer and more effective polynucleotide-based products, enhancing their accessibility and adoption.
   

Middle East and Africa: The polynucleotides injectables market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• The growing preference for non-invasive and minimally invasive aesthetic treatments among men and women in Saudi Arabia, stimulated by self-consciousness and cultural preference for youthful and rejuvenated skin, is anticipated to propel the market growth in the country.
   
• Additionally, government initiatives in Saudi Arabia, such as Vision 2030, which promote the expansion of the healthcare sector, are also increasing the access to innovative treatments and boosting the market for polynucleotide injectables.
   

 Polynucleotides Injectables Market Share

The top 4 players of the polynucleotides injectable industry account for approximately 40% of the market share which includes companies such as Croma Pharma, DermaFocus, Mastelli, Genoss, among others. With every firm introducing minimal invasive and advanced technologies, modernization is extremely important.
 

Moreover, strategic partnerships with beauty clinics, dermatologists, cosmetics research institutes, and government agencies play a primary role in advancing the development of new products and getting the necessary permits. The enhancement of public awareness through the social media platform, will encourage more individuals to seek the treatment, assisting market players to strengthen their position in this growing sector.
 

 Polynucleotides Injectables Market Companies

Some of the eminent market participants operating in the polynucleotides injectables industry include:

• AMEELA
• BR Pharm
• Croma Pharma
• DermaFocus
• Fox Pharma
• Genoss
• Lkc Pharma
• Mastelli
• Pluryal
• Promoitalia Laboratories
   
• Croma Pharma offers innovative solutions such as Saypha Rich and Saypha Volume Plus, hyaluronic acid-based dermal fillers that enhance skin hydration, elasticity, and volume.
   
• Mastelli is expanding its global reach, leveraging strategic distributor agreements to export its polynucleotide-based injectables across EU and non-EU markets.
   
• Pluryal offers a range of dermal fillers and skin boosters, including products enriched with polynucleotides.
   

Polynucleotides Injectables Industry News:

• In October 2023, LG Chem and BR Pharm collaborated to develop and seek approval for HP Vitaran, a skin booster containing polynucleotides (PN) from salmon and fish reproductive cells, for the Chinese market. The collaboration combined LG Chem's expertise with BR Pharm's regenerative medicine technology.
   
• In June 2023, Amedica rebranded its polynucleotide product line from Nucleadyn to Ameela. The Ameela portfolio includes three products: Ameela Eyes, Ameela Rejuvenation, and Ameela Face. This rebranding strengthened Amedica's position in the aesthetic market by offering specialized solutions for various skin concerns, enhancing brand recognition, and driving broader adoption of polynucleotide treatments.
   

The polynucleotides injectables market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Application

• Eyes
• Lips
• Forehead
• Jawline and cheekbones
• Other applications 

Market, By End Use

• Medical spas
• Aesthetic and cosmetic centers
• Hospitals

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE